• Profile
Close

Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: A pharmacokinetic modelling and clinical study

The Lancet HIV Jan 11, 2019

Rabie H, et al. - In this prospective, open-label, one-group, one-sequence study, authors assessed 96 young HIV-infected children with tuberculosis in South African provinces to examine the efficacy of lopinavir–ritonavir super-boosting therapy in candidates during rifampicin-based tuberculosis treatment. They prescribed the candidates with standard 4:1 ratio of lopinavir–ritonavir in the absence of rifampicin-based anti-tuberculosis treatment and super-boosting of lopinavir–ritonavir with additional ritonavir twice a day orally to achieve a 1:1 ratio during rifampicin therapy. Overall, they observed positive and safe impacts of super-boosting but with limited preference and poor acceptability. Hence, they recommended its access to improve public health.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay